CSCO BC | Academician Jinming Yu: Exploring New Directions in Breast Cancer Treatment and Empowering the Next Generation of Oncology Leaders

CSCO BC | Academician Jinming Yu: Exploring New Directions in Breast Cancer Treatment and Empowering the Next Generation of Oncology Leaders

At the 2025 China National Breast Cancer Conference, CSCO President and Director of Shandong Cancer Hospital, Academician Jinming Yu, delivered a keynote address titled “Precision Integration of Radiotherapy and Immunotherapy in Breast Cancer.” His presentation explored not only the evolving role of radiotherapy in breast cancer treatment but also offered key insights into strengthening China’s scientific innovation capacity in oncology. Following the session, Oncology Frontier invited Academician Yu to share his perspectives on the clinical application of radiotherapy in breast cancer, strategies for advancing China's global competitiveness in oncology, and his long-standing commitment to cultivating young academic talent.
APASL Keynote Address | Academician Jiahong Dong: The Era of Precision Liver Surgery Powered by Smart Technology Has Arrived

APASL Keynote Address | Academician Jiahong Dong: The Era of Precision Liver Surgery Powered by Smart Technology Has Arrived

Editor’s Note: On the morning of March 28, the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025) officially opened. During the keynote session, APASL 2025 Scientific Committee Chair, Academician Jiahong Dong of Beijing Tsinghua Changgung Hospital, delivered a keynote speech titled “Precision Surgical Treatment of Liver Diseases” and participated in an in-depth interview with International Hepatology. In his address, Academician Dong presented IDEAL—China’s first multimodal intelligent system for precision surgical decision-making in liver diseases. He explained how IDEAL enhances the accuracy, safety, and minimally invasive nature of liver surgery, offering patients greater health benefits. Dong also emphasized the transformative role of digital technologies in surgical care, predicting their impact across clinical evaluation, surgical planning, decision-making, and data management, thus accelerating innovation in the field of hepatobiliary surgery.
EBMT 2025 | Prof. Fang Liu: From Predictive Models to Rare Disease Cures—Advancing Pediatric Cord Blood Transplantation

EBMT 2025 | Prof. Fang Liu: From Predictive Models to Rare Disease Cures—Advancing Pediatric Cord Blood Transplantation

At the 2025 EBMT Annual Meeting, cord blood transplantation (UCBT) emerged as a transformative strategy in the treatment of pediatric hematologic malignancies. Hematopoietic stem cell transplantation (HSCT) remains a life-saving therapy, and UCBT is gaining attention for its unique clinical advantages. During the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025) held in Florence, Italy, Hematology Frontier invited Prof. Fang Liu from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to share insights into the current role of transplantation in pediatric hematologic malignancies. She also highlighted her team’s latest findings in UCBT and discussed significant developments in the field of pediatric transplantation presented at the conference.
EBMT 2025 | Prof. Qifa Liu: Emerging Strategies for GVHD Prevention—Mesenchymal Stem Cells and Fecal Microbiota Transplantation

EBMT 2025 | Prof. Qifa Liu: Emerging Strategies for GVHD Prevention—Mesenchymal Stem Cells and Fecal Microbiota Transplantation

The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025) was held from March 30 to April 2 in the historic city of Florence, Italy. As one of the most influential global events in the field of hematology, the Annual Meeting gathered over 5,000 experts and scholars from around the world to explore cutting-edge advances in hematopoietic stem cell transplantation (HSCT) and cellular therapy.At the Annual Meeting , Hematology frontier had the honor of speaking with Professor Qifa Liu of the Nanfang Hospital, Southern Medical University. Prof. Liu shared his insights on the latest progress in graft-versus-host disease (GVHD) prevention and treatment, particularly focusing on the innovative applications of mesenchymal stem cells (MSCs) and fecal microbiota transplantation (FMT). He also reflected on the impact of this year’s Annual Meeting on ongoing and future clinical research directions.
EBMT 2025 | Prof. Erlie Jiang & Dr. Mingyang Wang: Using CBFB-MYH11 Fusion Transcript Ratios to Guide Transplant Timing in Low-Risk AML

EBMT 2025 | Prof. Erlie Jiang & Dr. Mingyang Wang: Using CBFB-MYH11 Fusion Transcript Ratios to Guide Transplant Timing in Low-Risk AML

Hematopoietic stem cell transplantation (HSCT) remains a curative treatment for numerous hematologic disorders. Despite its life-saving potential, many clinical challenges persist, particularly concerning patient selection, transplant timing, and long-term management. To enhance academic exchange and practical insights in the field of transplantation, Hematology Frontier launched the special feature "Transplantation Pathways Spotlight" during the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025). This column brings together leading experts from China and abroad to discuss full-cycle transplant care, from pre-transplant assessment through to long-term recovery, aiming to establish an integrated and forward-looking framework for clinical transplantation.
EAU 2025丨Dr. Siamak Daneshmand Shares the Potential of Oncolytic Virus Therapy for NMIBC Patients

EAU 2025丨Dr. Siamak Daneshmand Shares the Potential of Oncolytic Virus Therapy for NMIBC Patients

For patients with non-muscle-invasive bladder cancer (NMIBC) who do not respond to Bacillus Calmette-Guérin (BCG) therapy, clinicians and researchers are actively exploring novel treatment strategies. Among these, oncolytic virus therapy has emerged as a promising approach. At the 40th Annual EAU Congress, Dr. Siamak Daneshmand from the University of Southern California (USC) presented two key studies on oncolytic viruses—the BOND-003 P cohort and the PIVOT-006 trial. UroStream invited Professor Daneshmand to discuss the mechanism of action, safety, efficacy, and future directions of this innovative therapy.